The landscape of prognostic and immunological role of myosin light chain 9 (MYL9) in human tumors

Abstract

Introduction: Recent studies have shown that myosin light chain 9 (MYL9) plays a vital role in immune infiltration, tumor invasion, and metastasis; however, the prognostic and immunological role of MYL9 has not been reported. The purpose of this study was to explore the potential prognostic and immunological roles of MYL9 in human cancers by public datasets mainly including the cancer genome atlas (TCGA) and Gene expression omnibus. Methods: The expression pattern and prognostic value of MYL9 were analyzed across multiple public datasets in different cancer. The correlations between MYL9 expression and immune infiltration among multiple cancers were analyzed by using the TIMER2.0. The MYL9-related gene enrichment analysis was implemented by mainly using KEGG and GO datasets. Results: MYL9 was lowly expressed in most cancers, such as breast cancer, lung adenocarcinoma and squamous cell carcinoma, and stomach adenocarcinoma; but it was highly expressed in several cancers, such as cholangiocarcinoma, head and neck squamous cell carcinoma, and liver hepatocellular carcinoma. Furthermore, MYL9 expression was distinctively associated with prognosis in adrenocortical carcinoma, colon adenocarcinoma, brain glioma, lung cancer, ovarian cancer, gastric cancer, breast cancer, blood cancer, and prostate cancer patients. The expressions of MYL9 were significantly associated with the infiltration of cancer-associated fibroblasts, B cell, CD8 + T cell, CD4 + T cell, macrophage, neutrophil, dendritic cell in different tumors as well as immune markers. In addition, we found that the functional mechanisms of MYL9 involved muscle contraction and focal adhesion.Conclusion: MYL9 can serve as a prognostic signature in pan-cancer and is associated with immune infiltration. This pan-cancer study is the first to show a relatively comprehensive understanding of the prognostic and immunological roles of MYL9 across different cancers.

Proteomic Analysis of Endometrial Cancer Tissues from Patients with Type 2 Diabetes Mellitus

“…The expression of MYL 9 in cancer cells differs with different types of cancers. In ECs, the expression of MYL 9 has been reported to be lower than in the normal tissues [30]. As the proteins associated with cancer cells are more expressed in patients with diabetes, it reflects the aggressive nature of cancer in these patients.…”

Retinoid acid receptor β mechanically regulates the activity of pancreatic cancer cells

“…Phosphorylation of MLC-2 modulates force generation by non-muscle myosin II, the primary contractile apparatus in cancer cells, and is therefore associated with the regulation of cancer cell migration, invasion and mechanosensing. MLC-2 is upregulated in different cancer types, including melanoma [45], hepatocellular carcinoma [24], oesophageal squamous cell carcinoma [46], and PDAC [47], making it an important prognosis and therapeutic target in cancer biomechanics [48]. Analysis of MLC-2 expression in normal cancer adjacent and PDAC tissue microarrays (TMAs) confirmed a 2.5-fold increase in MLC-2 expression in PDAC (Fig.…”

A Transcriptomic Response to Lactiplantibacillus plantarum-KCC48 against High-Fat Diet-Induced Fatty Liver Diseases in Mice

“…Myl9 plays a critical role in immune infiltration, tumor invasion, and metastasis. The expression of MYL9 was significantly associated with prognosis in several cancers [ 74 ]. MYL9 mRNA expression was higher in mice liver fed with HFD compared to control groups.…”